Stable transformation and cloning mediated by piggyBac vector and RNA interference knockdown of Drosophila ovarian cell line.

In Vitro Cell Dev Biol Anim

Department of Sciences, Faculty of Science, Ibaraki University, Mito, 310-8512, Japan.

Published: December 2011

An in vitro study is a powerful method for elucidating gene functions in cellular and developmental events. However, until date, no reliable in vitro transformation, cloning, or knockdown system has been reported for Drosophila cells, with the exception of S2 and Kc cells. In this study, we demonstrated that the piggyBac vector stably integrates donor DNA into ovarian somatic sheets derived from follicle stem cells. The transformed ovarian somatic sheet cells were easily cloned with a new piggyBac selection vector carrying enhanced green fluorescent protein and dihydrofolate reductase genes, egfp, and dhfr, respectively, in culture media containing methotrexate, an inhibitor of DNA synthesis. Donor egfp continued to be expressed at a high level in long-term culture. Furthermore, the translation of donor egfp was inhibited by treatment with double-stranded RNA derived from the target gene. The transfection and cloning methods mediated by the piggyBac vector would thus be useful for future analyses of gene functions in OSS cells and possibly be applicable to other Drosophila cell lines.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11626-011-9463-yDOI Listing

Publication Analysis

Top Keywords

piggybac vector
12
transformation cloning
8
mediated piggybac
8
gene functions
8
ovarian somatic
8
donor egfp
8
cells
5
stable transformation
4
cloning mediated
4
piggybac
4

Similar Publications

Current Non-Viral-Based Strategies to Manufacture CAR-T Cells.

Int J Mol Sci

December 2024

Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.

The successful application of CAR-T cells in the treatment of hematologic malignancies has fundamentally changed cancer therapy. With increasing numbers of registered CAR-T cell clinical trials, efforts are being made to streamline and reduce the costs of CAR-T cell manufacturing while improving their safety. To date, all approved CAR-T cell products have relied on viral-based gene delivery and genomic integration methods.

View Article and Find Full Text PDF

The white gene as a transgenesis marker for the cricket Gryllus bimaculatus.

G3 (Bethesda)

October 2024

Laboratoire de Biologie et Modélisation de la Cellule, École Normale Supérieure de Lyon, CNRS UMR5239, Université Claude Bernard Lyon 1, 9 rue du Vercors, 69007 Lyon, France.

The cricket Gryllus bimaculatus is an emerging model insect of the order Orthoptera that is used in a wide variety of biological research themes. This hemimetabolous species appears highly complementary to Drosophila and other well-established holometabolous models. To improve transgenesis applications in G.

View Article and Find Full Text PDF

Objectives: To establish a cell line stably expressing the transient receptor potential melastatin 2 (TRPM2) channel for screening TRPM2 inhibitors based on PiggyBac transposition system.

Methods: A plasmid PiggyBac-human TRPM2 (pPB-hTRPM2) eukaryotic expression vector was constructed using PiggyBac transposition system. The plasmid and a helper plasmid were co-transfected into HEK293T cells to express TRPM2, which was identified by fluorescence and patch-clamp assays.

View Article and Find Full Text PDF

Background: The non-viral production of CAR-T cells through electroporation of transposon DNA plasmids is an alternative approach to lentiviral/retroviral methods. This method is particularly suitable for early-phase clinical trials involving novel types of CAR-T cells. The primary disadvantage of non-viral methods is the lower production efficiency compared to viral-based methods, which becomes a limiting factor for CAR-T production, especially in chemotherapy-pretreated lymphopenic patients.

View Article and Find Full Text PDF
Article Synopsis
  • CD19-targeted CAR T cell therapies have transformed treatment for B-cell malignancies, but over half of patients face treatment failure due to antigen escape and low cell persistence.
  • The effectiveness of these therapies is impacted by cell functionality and potential toxicities from systemic cytokines.
  • A new virus-free engineering system, Quantum pBac™ (qPB), has been developed to produce dual-targeted CAR-T cells that are efficient, robust, and safe, potentially improving treatment effectiveness and accessibility.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!